<DOC>
<DOCNO>
EP-0005646
</DOCNO>
<TEXT>
<DATE>
19791128
</DATE>
<IPC-CLASSIFICATIONS>
A61K-31/4738 C07D-209/94 C07D-233/00 C07D-209/90 A61K-31/475 A61P-25/00 A61K-31/4745 C07D-471/00 A61P-25/18 C07D-209/00 C07D-471/04 <main>C07D-471/06</main> C07D-233/74 C07D-471/06 
</IPC-CLASSIFICATIONS>
<TITLE>
isoquinoline compounds, their preparation, pharmaceutical formulations containing them and intermediates.
</TITLE>
<APPLICANT>
lilly industries ltdgb<sep>lilly industries limited<sep>lilly industries limitedhenrietta house henrietta placelondon w1m 0edgb<sep>lilly industries limited<sep>
</APPLICANT>
<INVENTOR>
horwell david christopher<sep>tupper david edward<sep>horwell, david christopher<sep>tupper, david edward<sep>horwell, david christopher36, the findings fernhill roadcove farnborough hampshiregb<sep>tupper, david edward118, staplehurst roman woodbracknell berkshiregb<sep>horwell, david christopher<sep>tupper, david edward<sep>horwell, david christopher36, the findings fernhill roadcove farnborough hampshiregb<sep>tupper, david edward118, staplehurst roman woodbracknell berkshiregb<sep>
</INVENTOR>
<ABSTRACT>
isoquinoline compounds of the following formula are  described:    wherein the moiety a-b represents a group of formula:   -ch₂-nr³- or -nr³-ch₂-;   wherein r³ represents hydrogen, c₁₋₆ alkyl, c₃₋₆ cycloalkyl,  c₃₋₆ cycloalkyl-c₁₋₄ alkyl, optionally substituted benzyl, c₃₋₆  alkenyl or c₁₋₄ alkanoyl;   wherein r represents hydrogen, c₁₋₆ alkyl, c₃₋₆ cycloalkyl, or  optionally substituted benzyl;   wherein r¹ and r² each represent hydrogen or taken  together represent a chemical bond; and wherein x is  hydrogen or halogen; or an acid-addition salt thereof.  the compounds are pharmaceutically and especially  useful in the treatment of disorders of the central nervous  system.  
</ABSTRACT>
</TEXT>
</DOC>
